Compare M & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | M | IRTC |
|---|---|---|
| Founded | 1830 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.8B |
| IPO Year | N/A | 2016 |
| Metric | M | IRTC |
|---|---|---|
| Price | $20.18 | $151.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $20.60 | ★ $217.31 |
| AVG Volume (30 Days) | ★ 6.3M | 669.9K |
| Earning Date | 03-05-2026 | 02-19-2026 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | ★ 331.62 | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $22,712,000,000.00 | $702,573,000.00 |
| Revenue This Year | N/A | $27.42 |
| Revenue Next Year | N/A | $17.05 |
| P/E Ratio | $11.69 | ★ N/A |
| Revenue Growth | N/A | ★ 25.45 |
| 52 Week Low | $9.76 | $92.52 |
| 52 Week High | $24.41 | $212.00 |
| Indicator | M | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 35.90 | 33.12 |
| Support Level | $20.05 | $158.90 |
| Resistance Level | $20.53 | $174.36 |
| Average True Range (ATR) | 0.71 | 8.79 |
| MACD | -0.22 | -2.03 |
| Stochastic Oscillator | 5.53 | 0.37 |
Founded in 1858 and based in New York City, Macy's operates about 450 stores under the Macy's name, nearly 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's names, and more than 170 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances constitute about 62% of Macy's sales.
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.